Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1996 Jan;73(2):236–240. doi: 10.1038/bjc.1996.41

Lymphocyte recovery and clinical response in multiple myeloma patients receiving interferon alpha 2 beta after intensive therapy.

B C Millar 1, J B Bell 1, R L Powles 1
PMCID: PMC2074310  PMID: 8546912

Abstract

The recovery of immunoregulatory cells in the peripheral blood of patients with multiple myeloma receiving maintenance therapy with interferon alpha 2 beta (IFN-alpha 2 beta) after intensive therapy with high-dose melphalan and autologous bone marrow or peripheral blood stem cell rescue was studied. IFN-alpha 2 beta significantly inhibited the recovery of CD3+, CD4+, CD8+, CD56+/CD3- and CD16+/CD3- lymphocytes compared with numbers found in patients who had no further post-transplant treatment, but had no effect on the recovery of CD19+ cells. Among patients who did not receive IFN-alpha 2 beta, the number of CD8+, CD56+/CD3- and CD16+CD3- lymphocytes recovered to values similar to normal volunteers with increasing time after intensive therapy, however the number of CD4+ cells remained significantly below levels found in normal volunteers. Although CD16+/CD3- and CD56+/CD3- cell numbers were reduced in patients receiving IFN-alpha 2 beta, natural killer (NK) activity was not affected. The levels of soluble interleukin 2 receptor (sIL-2R) were similar in all patients and IL-2 was not detected in any patient. At the time of writing, of the total of 69 patients, seven have relapsed, of whom three were receiving IFN-alpha 2 beta, however there was no correlation between the absolute numbers of any lymphocyte subset with imminent relapse. The data suggest that the recovery of a specific lymphocyte subset(s) in peripheral blood is unlikely to be associated with the maintenance of response after intensive therapy.

Full text

PDF
236

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abbas A. K. T lymphocyte-mediated suppression of myeloma function in vitro. I. Suppression by allogeneically activated T lymphocytes. J Immunol. 1979 Nov;123(5):2011–2018. [PubMed] [Google Scholar]
  2. Attal M., Huguet F., Schlaifer D., Payen C., Laroche M., Fournie B., Mazieres B., Pris J., Laurent G. Intensive combined therapy for previously untreated aggressive myeloma. Blood. 1992 Mar 1;79(5):1130–1136. [PubMed] [Google Scholar]
  3. Bergmann L., Mitrou P. S., Weber K. C., Kelker W. Imbalances of T-cell subsets in monoclonal gammopathies. Cancer Immunol Immunother. 1984;17(2):112–116. doi: 10.1007/BF00200046. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Cimino G., Avvisati G., Amadori S., Cava M. C., Giannarelli D., Di Nucci G. D., Magliocca V., Petrucci M. T., Poti G., Sgadari C. High serum IL-2 levels are predictive of prolonged survival in multiple myeloma. Br J Haematol. 1990 Jul;75(3):373–377. doi: 10.1111/j.1365-2141.1990.tb04351.x. [DOI] [PubMed] [Google Scholar]
  5. Dianzani U., Pileri A., Boccadoro M., Palumbo A., Pioppo P., Bianchi A., Camponi A., Fossati G., Battaglio S., Massaia M. Activated idiotype-reactive cells in suppressor/cytotoxic subpopulations of monoclonal gammopathies: correlation with diagnosis and disease status. Blood. 1988 Sep;72(3):1064–1068. [PubMed] [Google Scholar]
  6. Einhorn S., Ahre A., Blomgren H., Johansson B., Mellstedt H., Strander H. Interferon and natural killer activity in multiple myeloma. Lack of correlation between interferon-induced enhancement of natural killer activity and clinical response to human interferon-alpha. Int J Cancer. 1982 Aug 15;30(2):167–172. doi: 10.1002/ijc.2910300207. [DOI] [PubMed] [Google Scholar]
  7. Firestein G. S., Roeder W. D., Laxer J. A., Townsend K. S., Weaver C. T., Hom J. T., Linton J., Torbett B. E., Glasebrook A. L. A new murine CD4+ T cell subset with an unrestricted cytokine profile. J Immunol. 1989 Jul 15;143(2):518–525. [PubMed] [Google Scholar]
  8. Gonzalez M., San Miguel J. F., Gascon A., Moro M. J., Hernandez J. M., Ortega F., Jimenez R., Guerras L., Romero M., Casanova F. Increased expression of natural-killer-associated and activation antigens in multiple myeloma. Am J Hematol. 1992 Feb;39(2):84–89. doi: 10.1002/ajh.2830390203. [DOI] [PubMed] [Google Scholar]
  9. Joshua D. E. Biology of multiple myeloma--host-tumour interactions and immune regulation of disease activity. Hematol Oncol. 1988 Apr-Jun;6(2):83–88. doi: 10.1002/hon.2900060204. [DOI] [PubMed] [Google Scholar]
  10. Klingemann H. G., Grigg A. P., Wilkie-Boyd K., Barnett M. J., Eaves A. C., Reece D. E., Shepherd J. D., Phillips G. L. Treatment with recombinant interferon (alpha-2b) early after bone marrow transplantation in patients at high risk for relapse [corrected]. Blood. 1991 Dec 15;78(12):3306–3311. [PubMed] [Google Scholar]
  11. Massaia M., Attisano C., Peola S., Montacchini L., Omedé P., Corradini P., Ferrero D., Boccadoro M., Bianchi A., Pileri A. Rapid generation of antiplasma cell activity in the bone marrow of myeloma patients by CD3-activated T cells. Blood. 1993 Sep 15;82(6):1787–1797. [PubMed] [Google Scholar]
  12. Massaia M., Bianchi A., Dianzani U., Camponi A., Attisano C., Boccadoro M., Pileri A. Defective interleukin-2 induction of lymphokine-activated killer (LAK) activity in peripheral blood T lymphocytes of patients with monoclonal gammopathies. Clin Exp Immunol. 1990 Jan;79(1):100–104. doi: 10.1111/j.1365-2249.1990.tb05134.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Massaia M., Dianzani U., Bianchi A., Camponi A., Boccadoro M., Pileri A. Defective generation of alloreactive cytotoxic T lymphocytes (CTL) in human monoclonal gammopathies. Clin Exp Immunol. 1988 Aug;73(2):214–218. [PMC free article] [PubMed] [Google Scholar]
  14. Millar B. C., Bell J. B. 2',5'-Oligoadenylate synthetase levels in patients with multiple myeloma receiving maintenance therapy with interferon alpha 2b do not correlate with clinical response. Br J Cancer. 1995 Dec;72(6):1525–1530. doi: 10.1038/bjc.1995.541. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Osterborg A., Masucci M., Bergenbrant S., Holm G., Lefvert A. K., Mellstedt H. Generation of T cell clones binding F(ab')2 fragments of the idiotypic immunoglobulin in patients with monoclonal gammopathy. Cancer Immunol Immunother. 1991;34(3):157–162. doi: 10.1007/BF01742306. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Osterborg A., Nilsson B., Björkholm M., Holm G., Mellstedt H. Natural killer cell activity in monoclonal gammopathies: relation to disease activity. Eur J Haematol. 1990 Sep;45(3):153–157. doi: 10.1111/j.1600-0609.1990.tb00443.x. [DOI] [PubMed] [Google Scholar]
  17. Parronchi P., De Carli M., Manetti R., Simonelli C., Sampognaro S., Piccinni M. P., Macchia D., Maggi E., Del Prete G., Romagnani S. IL-4 and IFN (alpha and gamma) exert opposite regulatory effects on the development of cytolytic potential by Th1 or Th2 human T cell clones. J Immunol. 1992 Nov 1;149(9):2977–2983. [PubMed] [Google Scholar]
  18. Ralph Q. M., Brisco M. J., Joshua D. E., Brown R., Gibson J., Morley A. A. Advancement of multiple myeloma from diagnosis through plateau phase to progression does not involve a new B-cell clone: evidence from the Ig heavy chain gene. Blood. 1993 Jul 1;82(1):202–206. [PubMed] [Google Scholar]
  19. Rohrer J. W., Lynch R. G. Immunoregulation of localized and disseminated murine myeloma: antigen-specific regulation of MOPC-315 stem cell proliferation and secretory cell differentiation. J Immunol. 1979 Sep;123(3):1083–1087. [PubMed] [Google Scholar]
  20. Sahota S., Hamblin T., Oscier D. G., Stevenson F. K. Assessment of the role of clonogenic B lymphocytes in the pathogenesis of multiple myeloma. Leukemia. 1994 Aug;8(8):1285–1289. [PubMed] [Google Scholar]
  21. San Miguel J. F., González M., Gascón A., Moro M. J., Hernández J. M., Ortega F., Jiménez R., Guerras L., Romero M., Casanova F. Lymphoid subsets and prognostic factors in multiple myeloma. Cooperative Group for the Study of Monoclonal Gammopathies. Br J Haematol. 1992 Mar;80(3):305–309. doi: 10.1111/j.1365-2141.1992.tb08137.x. [DOI] [PubMed] [Google Scholar]
  22. Uchida A., Yagita M., Sugiyama H., Hoshino T., Moore M. Strong natural killer (NK) cell activity in bone marrow of myeloma patients: accelerated maturation of bone marrow NK cells and their interaction with other bone marrow cells. Int J Cancer. 1984 Sep 15;34(3):375–381. doi: 10.1002/ijc.2910340314. [DOI] [PubMed] [Google Scholar]
  23. Vacca A., Di Stefano R., Frassanito A., Iodice G., Dammacco F. A disturbance of the IL-2/IL-2 receptor system parallels the activity of multiple myeloma. Clin Exp Immunol. 1991 Jun;84(3):429–434. [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES